Catalyst Event
CSPC Pharmaceutical Group Ltd (1093) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/12/2026, 12:00:00 AM
Executive President and Global Chief Medical Officer, Yongjiang Hei, was reported to have officially resigned to start his own venture. Estimated Low importance as executive changes in large firms often have limited immediate price impact.
Korean Translation
그룹의 집행총재 겸 글로벌 최고의학책임자(CMO)인 헤이융장(黑永疆)이 개인 창업을 위해 공식 사임한 것으로 보도됨. 대기업의 임원 교체는 즉각적인 주가 영향이 제한적이므로 낮은 중요도로 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM